STAT

Opinion: Using CRISPR for the ‘smaller wins,’ like making chemotherapy less toxic

Big breakthroughs in cancer treatment are great. But don't overlook the value of smaller wins, which can be big ones for patients.

Although the phrase “war on cancer” was first uttered in 1971, the breakthroughs in biomedical research that have emerged during this decade have supercharged the fight. The introduction of CRISPR-Cas9 — the molecular scissors that can edit DNA — makes the idea of powerful new tools to treat and prevent cancer feel tantalizingly close.

Ambitious efforts to prevent or beat cancer are important, but we can’t overlook or undervalue the incremental breakthroughs that could quickly reach patients and improve lives. What if, for example, we used CRISPR to make chemotherapy a bit less terrible for patients suffering with cancer now? That’s

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About BIO’s China Challenge, Zepbound Shortages, And More
BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.

Related Books & Audiobooks